BCR-ABL
Total cases (n=200)
BCR-ABL- (n=133)
BCR-ABL+ (n=67)
Response
No.
Low
BAALC
expression group (n=100)
High
BAALC
expression group (n=100)
p
No.
Low
BAALC
expression group (n=75)
High
BAALC
expression group (n=58)
p
No
Low
BAALC
expression group (n=25)
High
BAALC
expression group (n=42)
p
No
%
No
%
No
%
No
%
No
%
No
%
CR
99
55
55
44
44
0.120
78
47
62.7
31
53.4
0.284
21
8
32.0
13
31.0
0.929
CCR
73
43
43
30
30
0.056
62
38
50.7
24
41.4
0.287
11
5
20.0
6
14.3
0.541
Refractory
48
14
14
34
34
0.001
32
13
17.3
19
32.8
0.039
16
1
4.0
15
35.7
0.003
Relapse
26
12
12
14
14
0.674
16
9
12.0
7
12.1
0.990
10
3
12.0
7
16.7
0.604
Induction death
53
31
31
22
22
0.203
23
15
20.0
8
13.8
0.348
31
16
64.0
15
35.7
0.025
Alive/ Died
115/85
64/36
64/36
51/49
51/49
0.063
96/37
57/18
76.0/24.0
39/19
67.2/32.8
0.264
19/48
7/18
28.0/72.0
12/30
28.6/71.4
0.960
Table 2:
Clinical outcome according to BAALC expression in BCR-ABL− and BCR-ABL+ subgroups.
